Ultrahuman and Click Therapeutics Launch World's First Biomarker-Driven Migraine Management Tool
核心洞察
Ultrahuman (搜索) partners with Click Therapeutics (搜索) to develop Migraine PowerPlug (搜索), a biomarker-driven migraine (搜索) management tool based on FDA-authorized digital therapeutic technology.
The platform combines wearable biometric data with Click's CT-132 digital treatment to provide personalized migraine (搜索) insights and behavioral interventions for over one billion affected individuals.
Migraine PowerPlug (搜索) tracks sleep, heart rate variability, stress, and movement patterns to deliver tailored lifestyle guidance for migraine (搜索) prevention and management.
Ultrahuman (搜索), a global leader in wearable health technology, has announced a partnership with Click Therapeutics (搜索) to develop the Migraine PowerPlug (搜索), described as the world's first biomarker-driven migraine (搜索) management tool. The collaboration leverages Click Therapeutics' FDA-authorized prescription digital therapeutic technology to address the needs of more than one billion people affected by migraine worldwide.
Addressing a Critical Health Gap
Migraines impact an estimated 15 to 20 percent of the global population, with women experiencing migraines at nearly three times the rate of men. As a chronic neurological condition with no cure, migraine (搜索) represents one of the most disabling medical disorders and serves as the leading cause of disability among women aged 15-49, affecting work, family life, quality of life, and overall health.
"Helping people improve how they feel daily is core to Ultrahuman (搜索)'s mission. By integrating the underlying principles of Click Therapeutics (搜索)' digital migraine (搜索) treatment technology into our latest PowerPlug, we are enabling users to track and understand migraine-related patterns in real time, and then go further to turn those insights into actionable guidance," said Mohit Kumar, CEO of Ultrahuman.
Technology Integration and Clinical Foundation
The Migraine PowerPlug (搜索) represents a software-based feature within the Ultrahuman (搜索) platform that incorporates technology from Click's digital therapeutic CT-132, the first and only FDA-authorized digital treatment for the preventive treatment of migraine (搜索). CT-132 utilizes a proprietary, clinically validated approach to helping patients reduce migraine burden when used alongside existing medication.
The partnership combines Ultrahuman (搜索)'s biomarker analytics with Click's digital therapeutic technology and intellectual property. Unlike general wellness tools that offer only tracking capabilities, the Migraine PowerPlug (搜索) employs digital therapeutic principles to help users understand how biometric changes may correlate with potential triggers that can be managed through guided behavioral interventions.
Personalized Biomarker Monitoring
The platform focuses on tracking trends across sleep, recovery, stress, and activity, then translating those trends into practical, personalized lifestyle guidance. Many people with migraine (搜索) notice trends that manifest in daily physiology, with sleep quality, heart rate variability (HRV), stress load, and movement all influencing migraine frequency and intensity.
Migraine PowerPlug (搜索) includes goals for daily movement, sleep, and tailored hydration intake recommendations based on individual migraine (搜索) patterns. The system enables users to identify their own patterns, build consistency in critical areas, and implement science-backed strategies to improve resilience over time.
Women's Health Focus
Women's health has been central to Ultrahuman (搜索)'s roadmap, particularly following the recent acquisition of viO and its OvuSense technology. The company is working to support women across cycle types and hormonal profiles, recognizing that hormonal fluctuations are closely linked with migraine (搜索) patterns for many women. Ultrahuman's wellness insights aim to help women better understand these shifts and their relationship to migraine risk, frequency, and severity.
Market Launch and Availability
"Our partnership with Ultrahuman (搜索) will allow us to bring a much-needed personalized migraine (搜索) solution to people around the world," said David Benshoof Klein, CEO and founder of Click Therapeutics (搜索). "As digital health evolves, combining our clinically validated digital treatments with personalized consumer biometrics allows us to address an unmet need in over-the-counter care and the fast-growing wearables market."
The Migraine PowerPlug (搜索) is scheduled to launch for users via the Ultrahuman (搜索) app in early 2026 following a pilot phase. The rollout will include the United States, Canada, EU, India, Australia, and additional regions.
Clinical Context and Limitations
Migraine (搜索) management traditionally relies on occasional clinical visits, while symptoms and triggers occur daily. The Migraine PowerPlug (搜索) is designed around extending care beyond clinical settings, using wearable data and evidence-based interventions to provide real-time support.
The companies emphasize that the Migraine PowerPlug (搜索) functions as a general wellness and educational experience and is not intended to diagnose, treat, cure, or prevent any disease. It is not classified as a prescription digital therapeutic and does not replace professional medical care, with availability and features varying by region.